NEW YORK (360Dx) – HalioDx today announced its Immunoscore Colon assay has received CE-IVD marking.

The assay is to help clinicians assess the prognosis of primary colon cancer, in combination with the TNM classification and other clinical and biological features. The test evaluates the immune contexture of a patient's colon tumor and determines the likelihood that the cancer will spread, as well as the likelihood that the disease will recur after surgery, HalioDx said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.